Hyperfine

Hyperfine, Inc. is a medical device development company engaged in the development of, MRI solutions and non-invasive neural monitoring technology. The company was founded by Jonathan M. Rothberg on February 25, 2014 and is headquartered in Guilford, CT.

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Earnings data Q4 2025

Earnings data Q1 2026

Hyperfine reports record revenue in Q1 2023, eyes U.S. expansion

Hyperfine's Q1 2023 performance reflects strong revenue growth and strategic advancements in FDA clearances and partnerships. While facing significant expenses and cash burn, the company maintains a positive outlook for revenue and growth opportunities through innovation and market expansion.

Hyperfine reports record revenue in Q2 2023 amidst strategic expansion

Hyperfine's Q2 2023 earnings call reflects strong revenue growth, strategic focus on critical care and pediatric markets, and ongoing investment in technology and clinical studies. Despite financial challenges, the company maintains a positive outlook with a clear roadmap for future growth. Managing expenses and cash burn while pursuing innovation will be key to sustainable success.

Hyperfine reports robust Q3 earnings, eyes market expansion opportunities

Hyperfine's Q3 performance showcased strong revenue growth and improved financial metrics.
The company's focus on innovation and collaborations presents opportunities for market expansion.
Challenges include balancing investments in clinical studies while maintaining financial stability.

Hyperfine reports strong revenue growth and innovation focus for 2024

Hyperfine's Q4 2023 performance reflects robust revenue growth, strategic expansion into prestigious institutions, and a focus on cutting-edge healthcare solutions.
While facing financial challenges and a net loss, the company's commitment to innovation, FDA clearances, and market opportunities position it for future success.
With a strong 2024 revenue guidance, Hyperfine is poised to leverage its achievements in 2023, customer success, and international expansion to drive growth and profitability.

Hyperfine reports strong Q1 revenue growth and advances in medical imaging

Hyperfine's Q1 2024 performance reflects revenue growth driven by international contributions and advancements in clinical programs and commercial expansion.
While facing financial challenges and cash burn, the company maintains a positive outlook with plans for future growth and innovation in medical imaging technology.
Strategic strengths in AI software development and clinical applications position Hyperfine well to capture opportunities in the healthcare market and drive revenue growth.

Hyperfine reports robust Q3 growth, eyes international expansion opportunities

Hyperfine's Q3 2024 performance reflects strong revenue growth and operational efficiency improvements.
The company's focus on innovation, clinical efficacy, and market expansion presents opportunities for sustained growth.
However, managing cash burn, meeting revenue targets, and navigating competitive pressures remain key challenges for Hyperfine.

Hyperfine reports Q4 revenue dip, eyes growth through new products

Hyperfine's Q4 2024 performance showed revenue decline but full-year growth, with efforts to optimize operations and reduce cash burn in 2025. The company plans strategic product launches and market expansions while addressing challenges in managing expenses and improving margins. Opportunities lie in revenue growth, market expansion, and enhanced financial stability through operational enhancements and new product offerings.

Hyperfine reports Q1 revenue growth, focuses on diversified markets

Hyperfine's Q1 performance showed resilience with revenue from system sales and cash-saving measures. While facing challenges from academic institutions, the company is diversifying revenue streams. Opportunities lie in market expansion and product advancements for future growth.

Hyperfine reports strong Q2 performance, eyes growth through innovation

Hyperfine's Q2 2025 performance reflects revenue growth, improved gross margin, and positive market reception for new technologies. While facing financial challenges with a net loss and cash burn, the company's strategic strengths lie in product innovation and market diversification. Opportunities for growth through new product launches, international expansion, and partnerships position Hyperfine for a promising future.

Hyperfine reports record margins and revenue growth, eyes international expansion

Hyperfine's Q3 2025 performance showcased revenue growth, improved margins, and reduced cash burn. The company's strengths lie in strong market demand, international expansion progress, and innovation plans. Challenges include maintaining margins, managing cash burn, and meeting revenue guidance. Opportunities for Hyperfine include revenue growth, market expansion, and product enhancement.

Hyperfine reports strong Q4 revenue growth and expands market presence

Hyperfine's Q4 2025 performance reflects revenue growth and improved financial metrics. The company's strengths lie in market expansion, product approvals, and strengthened capital position. Challenges include managing cash burn, expenses, and sustaining growth momentum. Opportunities exist in driving growth across various healthcare markets and expanding market presence.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Hyperfine, Inc. is a medical device development company, which engages in providing imaging and monitoring through magnetic resonance imaging to revolutionize healthcare for people. It also develops imaging of health conditions through its Swoop portable magnetic resonance. The company was founded by Jonathan M. Rothberg and Ronald Walsworth on February 25, 2014 and is headquartered in Guilford, CT.